Louisiana Board of Pharmacy proposes major Controlled Dangerous Substances rule overhaul adopting 21 CFR Parts 1300–1399 by reference (anticipated effective June 20, 2026)

The Louisiana Board of Pharmacy CDS rulemaking project proposes restructuring LAC 46:LIII, Chapter 27 by adopting federal controlled substance regulations (21 CFR Parts 1300–1399) by reference, consolidating Louisiana-specific deviations into a dedicated section, and repealing redundant provisions. The project also indicates a distributor reporting approach where ARCOS-related reports would be provided upon request (rather than routine submissions). Compliance teams for CDS licensees should plan for potential harmonization with federal DEA requirements and identify Louisiana-specific deltas once finalized, given the stated anticipated effective date.